{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-183292","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2024-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.313827+00:00","generated_at":"2026-05-31T17:35:03.464959+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"enGene appoints Ron Cooper as CEO, promotes Raj Pruthi to CMO; Hanson departs as planned","bullets":["Ron Cooper appointed CEO and director effective July 22, 2024; Jason Hanson resigns but remains as strategic advisor.","Cooper receives $700k base salary, 60% bonus target, and inducement option for 1.25M shares at $8.81, vesting over 4 years.","Raj Pruthi promoted to CMO succeeding Richard Bryce, who departed July 19, 2024.","Hanson's transition amendment provides $390k severance payment; retains consulting role at $25k/month for 6 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-183292","json":"https://secwatch.observer/filing/0001193125-24-183292.json","markdown":"https://secwatch.observer/filing/0001193125-24-183292.md","text":"https://secwatch.observer/filing/0001193125-24-183292.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000119312524183292/0001193125-24-183292-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000119312524183292/d597787d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T17:35:03.464959+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c1519e39f0","claim":"Jason D. Hanson resigned as Chief Executive Officer at enGene Therapeutics Inc..","evidence_excerpt":"Mr. Hanson’s separation from the Company and resignation as a director became effective July 21, 2024, and his resignation is not the result of any disagreement with the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1980845/000119312524183292/0001193125-24-183292-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}